MedTrace Logo

Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

NCT05920408 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-11-08

No results posted yet for this study

Summary

A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid tumours.

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

EXS21546

EXS21546 Granule in Capsule

Sponsors & Collaborators

  • Biotrial

    collaborator INDUSTRY

  • Exscientia AI Limited

    lead INDUSTRY

Principal Investigators

  • Antoine Italiano, MD · Institut Bergonie, Bordeaux, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-11
Primary Completion
2023-09-27
Completion
2023-10-23

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05920408 on ClinicalTrials.gov